Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, Medtronic and Affera
Medtronic wins FDA approval for Affera mapping and ablation system
Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.
FDA approves Medtronic's Affera all-in-one pulsed field ablation system
Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation, Medtronic has done it again. | Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation for afib,
FDA approves Medtronic’s Affera mapping and ablation system with Sphere-9 catheter
This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.
Medtronic’s Innovative Affera System Gains FDA Approval, Boosting EP Market Prospects
Analyst Travis Steed from Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report) and keeping the price
Medtronic Gets FDA Approval for Affera Technology
Medtronic said the Food and Drug Administration approved its Affera mapping and ablation system with sphere-9 catheter.
FDA says Medtronic can study Affera pulsed field ablation system for treating ventricular tachycardia
Medtronic (NYSE: MDT) announced today that the FDA approved an early feasibility study to evaluate its Affera system for treating VT.
Medtronic’s Affera ablation system granted FDA approval
Medtronic (MDT) announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density mapping
FDA approves Medtronic’s Affera system for VT treatment study
The study aims to assess the Catheter and Affera system in patients who have ventricular tachycardia (VT) due to scarring from a previous myocardial infarction.
A new paradigm in electrophysiology: Medtronic receives FDA approval of Afferaâ„¢ Mapping and Ablation System and Sphere-9â„¢ Catheter
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug Administration (FDA) approval of the Afferaâ„¢ Mapping and Ablation System with Sphere-9â„¢ Catheter,
FDA approves Medtronic’s Affera cardiac mapping and ablation system and Sphere-9 catheter
Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA and RF energy.
3h
on MSN
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
medtechdive
10d
Medtronic to evaluate Affera in ventricular tachycardia
The FDA approved an early feasibility study of Medtronic’s Affera mapping and ablation system and Sphere-9 catheter in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
DOJ reaches settlement
DNA tests identify skull
Funeral home owners guilty
Grammy-winning singer dies
Murder-for-hire plot arrest
ABC News icon Jarriel dies
Recalls chicken products
Louisiana forces relocation
Strike kills 3 journalists
Madigan corruption trial
Kristy now Category 5
Browns sue city of Cleveland
4 astronauts return to Earth
Hack impacted 100M people
US mortgage rate climbs
AI firm sued over suicide
Seeks Jan. 6 case dismissal
Hit w/ discrimination claims
Exonerated after 22 years
USF basketball coach dies
New UN climate report
Judge blocks $8.5B deal
New student loan relief plan
US new home sales rise
Watchdog cautions firms
Sri Lanka attack alert
MO AG to probe Google
Announces layoffs, jet sales
Nigeria releases US exec
E. coli infections rise to 75
SC teen voting glitch
Related topics
Medtronic
Food and Drug Administration
Feedback